Latest advances in myelofibrosis treatment
Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, gives an overview of the latest treatment ...
VJHemOnc – Video Journal of Hematological Oncology
JAK inhibition for the early treatment of myelofibrosis
Ruben Mesa, MD, Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses ...
VJHemOnc – Video Journal of Hematological Oncology
What Do Patients with Myelofibrosis Need to Know?
A discussion with a panel of global key thought leaders regarding Myeloproliferative Neoplasms (MPNs). To learn more about ...
Oncology.TV
Being Marilyn…With Myelofibrosis—An MF Journey
When former teacher and avid quilter, Marilyn, discovered significant bruising on her legs, she wondered if the essential ...
Voices of MPN
Transplantation in patients with myelofibrosis
Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the use of stem cell ...
VJHemOnc – Video Journal of Hematological Oncology
Webinar: Myelofibrosis 2018
Myelofibrosis diagnosis and treatment options for patients and families. Recorded live April 11, 2018 What is Myelofibrosis?
AAMDSIF
Myelofibrosis treatment in 5 years
Srdan Verstovsek, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the future of the ...
VJHemOnc – Video Journal of Hematological Oncology
Drug extends survival for myelofibrosis patients
A drug that relieves the severe symptoms of a life-threatening bone marrow cancer called myelofibrosis also improves the survival ...
MD Anderson Cancer Center
Symptoms, Diagnosis, and QoL in Patients With Myelofibrosis
An overview of myelofibrosis, including symptoms of the disease, and how to measure disease burden, especially fatigue.
OncLiveTV
Primary Myelofibrosis | Hematology Medicine | Case Study | Medical Videos | V-Learning
This sqadia.com Medicine Hematology lecture will provide you a detailed in sight of Primary myelofibrosis. This medical lecture ...
sqadia.com
Mechanisms of bone marrow fibrosis in Myelofibrosis
Earn CME for related activities: https://www.naccme.com/oln In this presentation from the 2017 European Focus on ...
HMP Education
New therapies for myelofibrosis
Srdan Verstovsek, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX, outlines novel therapies ...
VJHemOnc – Video Journal of Hematological Oncology
Treating Intermediate/High-Risk Primary Myelofibrosis
Recommendations for treating patients who present with intermediate-risk or high-risk primary myelofibrosis. Website: ...
OncLiveTV
Treatment of Primary Myelofibrosis
Daniel J. DeAngelo, MD, PhD, describes the new guidelines by the National Comprehensive Cancer Network for myelofibrosis, ...
OncLiveTV
Understanding Myelofibrosis
Learn about myelofibrosis, how it is diagnosed, what the most common symptoms are, and how doctors monitor the disease.
Voices of MPN
The Use of Ruxolitinib in Myelofibrosis
A continued conversation on the use of ruxolitinib, including response rate, spleen size, platelet count, and anemia.
OncLiveTV
Management of Low-Risk Primary Myelofibrosis
Considerations for initiating therapy in patients with low-risk primary myelofibrosis and recommendations for selecting patients as ...
OncLiveTV
Challenges in myelofibrosis management
Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, shares his opinion on the most significant challenges in ...
VJHemOnc – Video Journal of Hematological Oncology
Treatment challenges in myelofibrosis
Treating myelofibrosis is accompanied by several complications that must be considered, including thrombocytopenia and ...
VJHemOnc – Video Journal of Hematological Oncology
Mayo Clinic Myelofibrosis Study
Ayalew Tefferi, M.D., a mayo clinic hematologist discusses the findings of a study for the treatment of symptoms of myelofibrosis.
Mayo Clinic
Improved survival of myelofibrosis patients receiving ruxolitinib post allo-HSCT
Eleni Gavriilaki, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discussess the long-term safety and ...
VJHemOnc – Video Journal of Hematological Oncology
Drs.Verstovsek & Mesa discuss latest Myelofibrosis updates from #SOHO2021: https://bit.ly/3hfP1kC
PeerView Oncology
Management of Myelofibrosis (MF)
Prof Andreas Reiter, University Medical Centre Mannheim, Heidelberg, Germany talks about diagnosing and treatment of MF ...
MPN Voice
Managing symptoms of myelofibrosis
Claire Harrison, MD, FRCP, FRCPath from Guys' and St Thomas' Hospital NHS Foundation Trust, London, UK discusses the ...
MPN Voice
Novel drugs and treatment strategies for myelofibrosis
Francesco Passamonti, MD, University of Insubria, Varese, Italy, discusses the key current themes in the treatment of myelofibrosis ...
VJHemOnc – Video Journal of Hematological Oncology
What Are the Treatment Options for Myelofibrosis?
When choosing a treatment for myelofibrosis (MF), where do you start? Dr. Laura Michaelis reviews the available options for MF ...
Patient Empowerment Network
Myelofibrosis for Patients
Ruben A. Mesa, M.D., FACP and Robyn M. Scherber, M.D., MPH of UT Health San Antonio MD Anderson Cancer Center discuss ...
UT Health San Antonio MD Anderson Cancer Center
Myelofibrosis: Diagnosis and Risk Stratification
Expert panelists Harry P. Erba, MD, PhD; Jamile M. Shammo, MD, FASCP, FACP; Ruben A. Mesa, MD, FACP; Srdan Verstovsek, ...
OncLiveTV
Primary Myelofibrosis Disease State
Daniel J. DeAngelo, MD, PhD, discusses typical presentation and diagnostic criteria for primary myelofibrosis, including molecular ...
OncLiveTV
Treating earlier in myelofibrosis
Srdan Verstovsek, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, explores earlier myelofibrosis ...
VJHemOnc – Video Journal of Hematological Oncology
Primary vs. Secondary Myelofibrosis: What’s the Difference?
Are primary and secondary myelofibrosis different? Dr. Joseph Scandura, a specialist in myeloproliferative neoplasms (MPNs), ...
Patient Empowerment Network
Mutations, Diagnosis, and Prognosis in Myelofibrosis
Srdan Verstovsek, MD, PhD, and Daniel J. DeAngelo, MD, PhD, provide insight on diagnostic criteria, prognostic factors and their ...
OncLiveTV
Myelofibrosis highlights at ASH 2020
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides his highlights on the latest ...
VJHemOnc – Video Journal of Hematological Oncology
Selinexor in myelofibrosis treatment
Selinexor inhibits karyopherin protein exportin 1 (XPO1) activity and is currently approved for diffuse large B-cell lymphoma ...
VJHemOnc – Video Journal of Hematological Oncology
New drug provides rapid, lasting relief for myelofibrosis patients
There are no approved drugs for this punishing and lethal bone marrow disease. Patients on an MD Anderson-led study gained ...
MD Anderson Cancer Center
Fedratinib for Primary Myelofibrosis
Ruben A. Mesa, MD, FACP, discusses the JAKARTA and JAKARTA-2 studies in primary myelofibrosis and comments on current ...
OncLiveTV
Primary Myelofibrosis: Risk Stratification
An overview regarding the evolution of prognostic scoring systems used to stratify patients who present with primary myelofibrosis.
OncLiveTV
Stem Cell Transplant for Myelofibrosis in the JAK2 Inhibitor Era
As recent discoveries have the potential to change the paradigm of how MPN and MDS are diagnosed and treated, it is imperative ...
HMP Education
Stem Cell Transplant for Myelofibrosis in the JAK2 Inhibitor Era
Earn CME for related activities: https://www.naccme.com/oln Filmed on location in Zagreb, Croatia during the European Focus on ...
HMP Education
Myelofibrosis: updates on JAK inhibitors
Prithviraj Bose, MBBS, MD Anderson Cancer Center, Houston, TX, explores the next generation JAK inhibitors, momelotinib and ...
VJHemOnc – Video Journal of Hematological Oncology
Ruben Mesa, MD: Myelofibrosis Patients Frequently Present Symptoms
Ruben Mesa, MD of Mays Cancer Center at UT Health, San Antonio discusses the visible symptoms and diagnosis process for ...
HCPLive
What can be learnt about using interferon in patients with myelofibrosis?
Treating patients who suffer from myelofibrosis with interferon used to be considered inappropriate due to the drug being poorly ...
VJHemOnc – Video Journal of Hematological Oncology
